Compare Glenmark Pharma with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WYETH LTD - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WYETH LTD GLENMARK PHARMA/
WYETH LTD
 
P/E (TTM) x 12.7 27.7 45.7% View Chart
P/BV x 1.8 5.3 33.9% View Chart
Dividend Yield % 0.5 1.3 42.0%  

Financials

 GLENMARK PHARMA   WYETH LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
WYETH LTD
Mar-13
GLENMARK PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs7121,044 68.1%   
Low Rs484818 59.1%   
Sales per share (Unadj.) Rs349.6298.6 117.1%  
Earnings per share (Unadj.) Rs32.857.2 57.3%  
Cash flow per share (Unadj.) Rs44.358.4 75.9%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.31.8 18.3%  
Book value per share (Unadj.) Rs198.6249.5 79.6%  
Shares outstanding (eoy) m282.1722.72 1,241.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.73.1 54.8%   
Avg P/E ratio x18.216.3 112.1%  
P/CF ratio (eoy) x13.515.9 84.6%  
Price / Book Value ratio x3.03.7 80.6%  
Dividend payout %6.129.7 20.5%   
Avg Mkt Cap Rs m168,62521,157 797.0%   
No. of employees `00012.00.5 2,446.5%   
Total wages/salary Rs m20,561400 5,140.2%   
Avg. sales/employee Rs Th8,196.013,787.4 59.4%   
Avg. wages/employee Rs Th1,708.1813.0 210.1%   
Avg. net profit/employee Rs Th768.52,643.3 29.1%   
INCOME DATA
Net Sales Rs m98,6556,783 1,454.4%  
Other income Rs m2,081353 590.3%   
Total revenues Rs m100,7367,136 1,411.7%   
Gross profit Rs m15,8581,617 980.5%  
Depreciation Rs m3,25927 12,252.3%   
Interest Rs m3,3466 60,834.5%   
Profit before tax Rs m11,3351,938 584.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-5 -32,780.4%   
Tax Rs m3,756632 594.2%   
Profit after tax Rs m9,2501,301 711.3%  
Gross profit margin %16.123.8 67.4%  
Effective tax rate %33.132.6 101.6%   
Net profit margin %9.419.2 48.9%  
BALANCE SHEET DATA
Current assets Rs m66,9686,984 958.9%   
Current liabilities Rs m40,2112,056 1,955.9%   
Net working cap to sales %27.172.6 37.3%  
Current ratio x1.73.4 49.0%  
Inventory Days Days8399 83.9%  
Debtors Days Days8124 339.2%  
Net fixed assets Rs m33,322244 13,639.7%   
Share capital Rs m282227 124.2%   
"Free" reserves Rs m55,7705,441 1,025.0%   
Net worth Rs m56,0525,668 988.9%   
Long term debt Rs m35,73825 142,950.0%   
Total assets Rs m132,8887,901 1,681.9%  
Interest coverage x4.4353.3 1.2%   
Debt to equity ratio x0.60 14,455.2%  
Sales to assets ratio x0.70.9 86.5%   
Return on assets %9.516.5 57.3%  
Return on equity %16.522.9 71.9%  
Return on capital %17.834.0 52.3%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m62,99815 414,463.2%   
Fx outflow Rs m22,8592,677 853.8%   
Net fx Rs m40,140-2,662 -1,507.9%   
CASH FLOW
From Operations Rs m13,242923 1,434.3%  
From Investments Rs m-6,990317 -2,205.7%  
From Financial Activity Rs m-7,387-481 1,535.8%  
Net Cashflow Rs m-2,971759 -391.4%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 6.9 11.3 61.1%  
FIIs % 34.4 7.2 477.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 30.4 34.5%  
Shareholders   56,727 21,978 258.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 17, 2019 01:51 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS